34 results about "Immune defence" patented technology

The invention relates to the technical field of chemical toxicology, in particular to an evaluation method for comprehensively analyzing the immune induction effect of a plasticizer by using caenorhabditis elegans, according to the evaluation method, a mother worm breeding mode is changed to replace a lysis solution to synchronize nematodes, experimental interference is reduced, the result accuracy is improved, monitoring indexes are newly increased, intestinal injuries and in-vivo bacterial indexes are increased, and the evaluation method is suitable for comprehensive analysis of the immune induction effect of the plasticizer. The evaluation is more accurate and reliable by combining oxidative stress indexes and performing two-dimensional comprehensive evaluation from an intestinal immune defense line and oxidative stress, and by drawing a multi-index monitoring shape graph, adopting a comprehensive biomarker response index analysis method and associating immune-related representative indexes, the evaluation accuracy is improved. According to the method, the change of each index and the immunity intensity on the caenorhabditis elegans under different exposure conditions are intuitively presented, the immune defense effect of the caenorhabditis elegans under the stress of the plasticizer can be quickly and effectively evaluated without transcriptome and metabonomics, and efficient evaluation is realized.

The invention discloses a Ruditapes philippinarum miR-263b inhibitor and application thereof, and finds that Ruditapes philippinarum miR-263b can regulate and control innate immune response of a host by targeting RpSC2, negatively regulates activation of an immune-related signal channel in a vibrio infection process, and further, on the basis of a molecular regulation and control mechanism, the Ruditapes philippinarum miR-263b inhibitor can be used for inhibiting the infection of vibrio. The invention discloses a specific inhibitor which is completely complementary with a miR-263b mature body sequence. Experimental data show that after Ruditapes philippinarum is injected with the miR-263b inhibitor, the expression level of miR-263b in vivo is reduced, and the inhibition effect of miR-263b on RpSC2 is effectively relieved, so that the expression level of a target gene RpSC2 is up-regulated, an NF-kappa B immune signal channel is activated, the immune defense capability of the Ruditapes philippinarum on vibrio anguillarum is enhanced, the death rate after infection is remarkably reduced, and the Ruditapes philippinarum is prevented from being infected. The in-vivo bacterium loading amount is obviously reduced, and the pathological injury of hepatopancreas tissue is obviously relieved.

The invention discloses a fermented ginseng-probiotic-natural antibacterial peptide composite oral liquid with an active immune defense function and a preparation method thereof, and belongs to the technical field of functional health food. The oral liquid is prepared by compounding a fermented ginseng matrix, an active probiotic preparation, a fly maggot source natural antibacterial peptide extract and auxiliary materials, and the activity of the components is guaranteed through a whole-course cold chain preparation process. On the basis of a microbial counterbalance theory, a human body active immune defense system is constructed by utilizing the synergistic effect of the fermented ginseng, the probiotics and the antibacterial peptide, and the limitation of traditional passive medical treatment is broken through; the shelf life of the product at 0-5 DEG C reaches 12 months, and the product is convenient to take and high in safety. The invention has the advantages of simple preparation process, wide raw material source and suitability for large-scale production, and has extremely high practical value in the field of human health protection.

The invention discloses a composition for preventing and treating oral diseases or conditions, a preparation method and application thereof. The external vesicles based on oral pathogenic bacteria are rich in nano-scale vesicles of immune activation and defense factors aiming at periodontitis, and after the external vesicles enter a body through oral mucosa administration, the external vesicles are passively targeted into lymph nodes related to the oral mucosa to induce mucosa immune specific antibody expression, so that the immune defense capacity to the pathogenic bacteria is improved. Preferably, a calcium phosphate shell is coated outside the oral bacterial outer vesicle, and the calcium phosphate shell can only be dissolved under an acidic condition, so that the engineered vesicle can be degraded after targeting to lymph nodes and being phagocytosed into dendritic cell lysosome, and the inflammatory reaction of a drug delivery area is avoided. The administration form of the sublingual disintegrating tablet can improve the bioavailability of the vaccine while local mucosal administration activates mucosal immunity, and the convenient administration form is also beneficial to the promotion and popularization of the periodontitis vaccine in clinical chair-side diagnosis and treatment or grassroots communities.

Provided are a composition for preventing and treating an oral disease or condition, a preparation method therefor, and the use thereof. The composition comprises extracellular vesicles derived from oral pathogenic bacteria. The extracellular vesicles are nanoscale vesicles rich in immune activation and defensive factors against pathogenic bacterial infection. Upon administration via the oral mucosa into a body, the vesicles are passively aimed at lymph nodes associated with the oral mucosa to induce the expression of a mucosal immunity-specific antibody, thereby enhancing immune defense against pathogenic bacteria. The extracellular vesicles of oral pathogenic bacteria are coated with a calcium phosphate shell, and the shell is soluble only under acidic conditions and degrades only after the extracellular vesicles are aimed at the lymph nodes and are phagocytosed into lysosomes of dendritic cells, thereby avoiding inflammatory reactions in an administration area. By using a sublingual disintegrating tablet as the form of administration, the bioavailability of a vaccine can be enhanced while achieving the local administration at the mucosa and activating mucosal immunity. Moreover, the composition is convenient to administer, which is conducive to the diagnosis and treatment of oral bacterial infectious diseases.

The invention discloses a functional food for improving immunity and belongs to the field of health-care foods. Comprising the following substances in parts by weight: 15-20 parts of chitosan oligosaccharide, 4-6 parts of astragalus polysaccharide, 2-4 parts of lucid ganoderma oligosaccharide, 2-4 parts of Chinese wolfberry oligosaccharide, 1-2 parts of codonopsis pilosula polysaccharide, 2-4 parts of ginseng oligosaccharide, 6-8 parts of lentinan, 6-10 parts of Chinese yam polysaccharide, 2-4 parts of oat peptide, 1-2 parts of pericarpium citri reticulatae polysaccharide, 6-8 parts of soybean peptide and 10-15 parts of whey protein peptide. The various components have a synergistic effect, the polysaccharide components can enhance the activity of immune cells, the peptide substances can promote the generation of immune factors, and the synergistic effect of the polysaccharide components and the peptide substances is beneficial for improving the immune defense capability of the body and improving the immunity of the human body.

The invention discloses a triple dynamic immune defense compound nutrient as well as a preparation method and application thereof, and relates to the technical field of immunity. The composition consists of red algae sulfated polysaccharide, beta-glucan, an elderberry extract, an echinacea purpurea extract, lactoferrin, nano-selenium, nano-zinc, citric acid and high fructose corn syrup according to a specific ratio. The core of the invention lies in that a triple dynamic immune defense shield theory of'oropharyngeal mucosa barrier (immediate defense)-system immune activation (short-term mobilization)-specific immune regulation (long-term consolidation) 'is proposed and constructed in the field of food for the first time, and through the cooperation of multiple mechanisms of physical blocking, biological inactivation, immune training and long-term regulation, the immunity of the oral pharyngeal mucosa is enhanced. And broad-spectrum prevention and auxiliary intervention on various viruses are realized. All the raw materials with homology of medicine and food and the food nutrition enhancer are adopted, so that the safety is high, and the applicable crowd is wide.

The present application relates to the field of agricultural biotechnology, in particular to locust immune related protein LmEaster gene and application thereof. The present application clones LmEaster gene and synthesizes double-stranded RNA, adopts injection method to treat locusts, and detects the mortality of locusts in each treatment and the expression amount change of related antibacterial peptide, and confirms that after interfering with LmEaster gene of locusts, the expression amount of antibacterial peptide of locusts is increased, the immune defense ability of locusts is increased, and then the mortality is reduced.

The invention relates to a shrimp culture method based on a precise thermal therapy strategy, and belongs to the field of aquaculture, the method comprises the following steps: regularly monitoring culture water temperature, preventing water temperature layering, and ensuring that the whole water temperature of the culture water is uniform and the temperature control is precise; when WSSV infection is detected, starting a thermal therapy method: raising the culture water temperature to 32-36 DEG C, or raising the temperature of a WSSV virus concentration area on a shrimp body at a fixed point while the culture water temperature is raised until the virus copy number is reduced or reduced to be negative; and a cooling and rehabilitation stage: reducing the water temperature to a normal culture temperature, continuously and regularly detecting the WSSV load of the shrimps after cooling, and confirming that the shrimps are not repeatedly infected with the WSSV and are stable in physiological status. According to the method, virus replication is intervened and inhibited through thermal therapy, the immune defense capability of the shrimps can be improved through thermal therapy at 32 DEG C or above, and the WSSV viruses in the shrimps are thoroughly removed.

The invention relates to the technical field of biological pharmacy, in particular to an immunopotentiator containing high-activity microbial protein peptide and a preparation method of the immunopotentiator. The immunopotentiator containing the high-activity microbial protein peptide comprises the following raw materials: beta-glucan, composite immune peptide, a freeze-drying protective agent, a metal organic framework and the balance of a stabilizer. The preparation method comprises the following steps: firstly, constructing an immune activation core skeleton by using beta-glucan, and activating a phosphorylation pathway by using Kluyveromyces marxianus source peptide in the composite immune peptide; the silkworm chrysalis protein peptide is in targeted combination with a receptor compound, so that the phagocytic rate of macrophages is increased; the recombinant lactoferrin peptide destroys a lipid bilayer of a microbial cell membrane through a cationic structural domain, activates a TLR4 pathway to promote lymphocyte differentiation, and ensures that the systematic immune defense efficacy is improved; specific antibacterial protein contained in the Fusarium brachypodium FXFB001 fermentation active protein extract can directly destroy a pathogen cell membrane structure and activate a TLR2 / 4 pathway to enhance innate immune response at the same time.

The application provides a bifidobacterium longum subsp. infantis and application thereof to enhancing adaptive immune response in early life, and belongs to the technical field of microorganisms. The bifidobacterium longum subsp. infantis provided by the application is named bifidobacterium longum subsp. infantis HH020, and the preservation number is GDMCC No:65828. Research shows that the bifidobacterium longum subsp. infantis can promote immune development in early life by regulating tryptophan metabolic pathways, enhance adaptive immune response in early life, thereby enhancing immune defense capacity and improving immune health.

The invention relates to the technical field of biological medicines, and particularly discloses a vaccine adjuvant composition as well as a preparation method and application thereof. The vaccine immune composition provided by the invention comprises GM-CSF and cortex albiziae saponin, and has the following advantages: 1, the vaccine immune composition can significantly improve the specific antibody level and the cytokine secretion efficiency, effectively promote the activation of killer T cells, efficiently induce the response of memory T cells, and construct a stable immune defense basis; 2, the immune level of the organism can be remarkably improved after challenge, the tissue injury risk is reduced by inhibiting replication and colonization of viruses in key target organs, and meanwhile, the body weight of the organism is promoted to be quickly recovered after challenge, so that the physiological homeostasis of the organism is better maintained; thirdly, the method is wide in adaptability and can be compatible with various veterinary vaccines such as foot-and-mouth disease vaccines, porcine reproductive and respiratory syndrome vaccines, pseudorabies vaccines and porcine circovirus type 2 vaccines. The method can be applied to the fields of research, development and preparation of vaccine adjuvants or vaccines and the like.

The invention discloses a pharmaceutical composition for inhalation and application thereof, the pharmaceutical composition comprises a therapeutically effective amount of interleukin-6 and a pharmaceutically acceptable solubilizer, the solubilizer is selected from at least one of cyclodextrin and a surfactant, and the weight percentage of the solubilizer in the composition is 0.5-60%. The composition effectively improves the solubility and stability of IL-6 by adding a solubilizer, making it suitable for pulmonary topical delivery. The pharmaceutical composition can safely induce the lung to generate neutrophil defensive infiltration in an aerosol inhalation mode, namely, the neutrophil is collected to the lung in advance on the premise of not causing obvious inflammatory response and tissue damage, so that the innate immune defense capability of a host to subsequent pathogen infection is enhanced.

The invention discloses a Brucella CTL (cytotoxic T lymphocyte) antigen epitope peptide and application thereof, the Brucella CTL antigen epitope peptide is any one or more of the following epitope polypeptides, and the amino acid sequences of the epitope polypeptides are shown as SEQ ID NO.1-3; according to the present invention, the CTL immune response is accurately activated, the immune defense requirement of Brucella intracellular infection is met, the core component is provided for the novel Brucella subunit vaccine, and the risks of virulence reversion, diagnosis interference and the like of the traditional attenuated live vaccine are avoided.

The invention relates to the technical field of biological medicine, in particular to application of salvianolic acid in preparation of an anti-tuberculosis drug. The invention provides application of salvianolic acid A or pharmaceutically acceptable salt thereof in preparation of the anti-tuberculosis drug, the molecular formula of the salvianolic acid A is C26H22O10, and the structural formula is shown in formula I. When the salvianolic acid A is applied to preparation of the anti-tuberculosis drug, a brand new material basis is provided for research and development of the anti-tuberculosis drug, damage of the drug to normal tissues of a human body is reduced, and the anti-tuberculosis drug can be applied to preparation of the anti-tuberculosis drug. Toxic and side effects are reduced. From the aspect of action mechanism, the salvianolic acid A has various biological activities such as inflammation resistance, oxidation resistance and immunoregulation, and can inhibit the growth and reproduction of mycobacterium tuberculosis and enhance the immune defense capability of the body to tubercle bacillus through the multi-target synergistic effect, thereby achieving the purpose of treating tuberculosis.

The invention relates to the technical field of vaccine adjuvants, in particular to an oil-in-water type nano emulsion adjuvant. The adjuvant comprises the following components in percentage by weight: 4.65%-8.51% of squalene or an oil phase matrix containing squalene, 0.45%-2.63% of a zwitterionic surfactant, 0.90%-5.19% of a polyoxyethylene nonionic surfactant and 0.22%-0.88% of a polyethylene glycol-fatty acid ester nonionic surfactant, and water is used as a continuous phase of the adjuvant. The vaccine can induce potent humoral immunity and cellular immunity responses, can induce antibody responses at mucous membrane parts such as intestinal tracts and vaginas after injection inoculation, and can induce an organism to generate comprehensive and effective immune defense aiming at pathogens.

The present invention relates to a malaria vaccine composition designed to elicit an immune response against Plasmodium falciparum by providing proteins or amino acid sequences, including PfGBP130 or PfGBP130-A surface antigen sequences. Upon administration to a human subject, the vaccine composition induces the production of specific anti-malaria antibodies. These antibodies are configured to inhibit the invasion of red blood cells by Plasmodium falciparum parasites and / or the antibodies binding to the antigens can cause the death of the parasites within red blood cells, thereby offering a preventive and / or therapeutic effect against malaria. The composition aims to enhance the immune defense mechanism in humans, reducing the incidence and severity of malaria infections by targeting critical stages of the parasite's lifecycle.

Compositions and methods for providing the hybrid benefit of treating biofilms on the surface of mammalian tissue, especially biofilms that occur in association with chronic wounds and burns, and simultaneously providing an antiseptic cleansing and maintenance of the stratum corneum of the tissue and other tissue surfaces, and an opportunity for the tissue to improve by engaging its own natural barrier and immunological defense properties. The compositions and methods prevent the re-establishment of biofilms by facilitating the reduction or eradication of the pathogen producing the biofilm before the biofilm can be established.

The invention belongs to the technical field of artificial intelligence assisted medical treatment, and particularly relates to a quantitative immune defense function evaluation system based on deep representation learning. Immune features are screened by comparing differences between acquired patients with immunodeficiency syndrome or severe sepsis and healthy control, dimension reduction is carried out by using a deep representation learning model of a variational auto-encoder, and a potential space is constructed. On the basis of the model, a healthy individual is taken as a reference, and a defense immunity score (DimmuScore) is obtained by calculating the distance between a patient and a healthy control in a potential space. As a single biomarker, the score can distinguish samples in different immune states and infection states with high accuracy. In addition, the method can be used as a quantitative index of disease severity in hepatitis B, tuberculosis and new coronavirus queues, and the gradient change of the method directly reflects the disease severity. The framework is verified in five infectious diseases, and a quantitative standard of cross-disease immune defense assessment is established for the first time.

The present application discloses a dark striped pufferfish L-type agglutinin VIP36, the amino acid sequence of which is shown as SEQ ID NO. 1, and the coding gene of which is shown as SEQ ID NO. 2. The present application also discloses the application of the dark striped pufferfish L-type agglutinin VIP36 in the preparation of a preparation with the efficacy of inhibiting Staphylococcus aureus, Vibrio parahaemolyticus, Aeromonas hydrophila and Vibrio harveyi. The present application firstly clones the coding gene of the dark striped pufferfish L-type agglutinin VIP36, constructs a prokaryotic expression vector of the dark striped pufferfish L-type agglutinin VIP36 and develops a recombinant protein; studies the use of the VIP36 recombinant protein in the immune defense function of the dark striped pufferfish, and the immune defense function includes regulating the homeostasis and health of the body, and the present application provides a theoretical basis for preventing diseases caused by pathogenic bacteria and a theoretical guidance for the healthy breeding of the dark striped pufferfish.

The invention discloses a lactobacillus johnsonii YS my4 strain with a cryptosporidium infection resisting effect and application of the lactobacillus johnsonii YS my4 strain. The preservation number of the YS my4 strain is CCTCC (China Center For Type Culture Collection) M 20253011. The strain disclosed by the invention has the characteristics of cholate resistance, intestinal juice resistance, strong adhesiveness and capability of inhibiting salmonella and staphylococcus aureus. In addition, the strain has no hemolytic rings, and the strain has no influence on body indexes and can increase the body weight after gavage of suckling rats, so that the strain is proved to be high in safety and can be applied to the fields of medicine and food. According to the invention, the YS my4 strain is intragastrically fed to a pseudo-sterile suckling mouse infected by cryptosporidium parvum, and it is found that the strain can activate immune defense of the intestinal tract of a host by improving the MAPK phosphorylation level of the host in the state of cryptosporidium parvum infection, so that the insect loading amount of the cryptosporidium parvum is remarkably reduced; meanwhile, the YS my4 strain can improve the expression level of tight junction proteins Occludin and CLDN4, relieve pathological damage of ileum tissues and improve the intestinal barrier function, and has important application value in prevention and treatment of cryptosporidium parvum infection.

The invention discloses a combined medicine for treating chronic prostatitis and a preparation method thereof. Comprising the following active components in percentage by mass: 12%-18% of tanshinone IIA, 18%-22% of cortex phellodendri total alkaloids, 25%-30% of astragalus polysaccharide, 10%-15% of taraxacin, 8%-12% of ligustrazine, 4%-6% of spina date seed total saponins, 2%-4% of schizandrin and 1%-3% of glycyrrhizic acid. The tanshinone IIA, the amur corktree bark total alkaloids and the taraxacin in the combined medicine are used for inhibiting expression of inflammatory factors such as COX-2, TNF-alpha and IL-6, so that prostate tissue inflammatory response is directly blocked; meanwhile, the astragalus polysaccharide and glycyrrhizic acid cooperate to activate T lymphocyte subgroups, regulate Th1 / Th2 balance and enhance the immune defense capability of the body, so that the recurrence rate is reduced.

The invention provides a precise feed for eleutheronema tetradactylum. The precise feed comprises the following components by weight: 51-61% of fish meal; 3-6% of krill powder; 4-6% of soybean meal; 18-20% of a digestion improving additive; 9-10% of a feed stable additive; 5-7% of a functional additive; wherein the digestion improving additive is used for improving the digestibility of protein and participates in intestinal microecological regulation; the feed stabilizing additive is used for stabilizing the block structure of the feed and preventing the feed from collapsing and dissolving in water. The feed prepared by the technical scheme can improve the intestinal health of eleutheronema tetradactylum, improve the digestive ability, and improve the antioxidant level and immune defense ability.

The invention discloses camel milk protein and application thereof. The invention relates to camel milk protein. The camel milk protein comprises a functional protein combination. The camel milk protein is derived from naturally-fermented camel milk, by comparing the change of protein properties and structures before and after natural fermentation, a proteomics technology is adopted, and evolution rules of protein types, content, functions and metabolic pathways are systematically analyzed, so that clear functional protein composition is obtained; the polypeptide has antibacterial, anti-inflammatory and metabolic regulation potentials, functional characteristics are changed from basic metabolism to immune defense, specific enrichment of ribosome and muscle cytoskeleton pathways and the like, and the polypeptide can be applied to food and dairy products.

The present application relates to aquaculture technology, in particular to a method for improving the growth and development speed and antibacterial ability of long oyster larvae by using taurine. The taurine soaking treatment of long oyster shell top larvae can promote the growth of larvae, accelerate the attachment metamorphosis process, and improve the survival rate after infection of Vibrio splendidus. The present application proves that taurine can improve the growth and development speed and immune defense ability of long oyster larvae, and has broad application prospects in shortening the oyster breeding cycle, improving the success rate and seed quality of breeding, promoting the green development of oyster culture industry, etc.

The invention relates to the field of detection of mucosal immune defense, in particular to bifidobacterium bifidum and application of the bifidobacterium bifidum in preparation of a preparation for immunoregulation and intestinal barrier repair. The bifidobacterium bifidum is a bifidobacterium bifidum BB16 of which the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.33423, and the bifidobacterium bifidum is a bifidobacterium bifidum BB16. The BB16 strain is preserved in China General Microbiological Culture Collection Center (CGMCC) on January 15, 2025, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The BB16 strain has the function of directly promoting secretion of mucosal immune barrier SIgA.

The invention relates to a method of predicting an outcome of a breast cancer subject, comprising determining or receiving the result of a determination of a gene expression profile comprising the expression levels of four or more genes selected from a first, a second and / or a third gene expression profile, wherein the first gene expression profile comprising one or more immune defense response genes selected from the group consisting of: AIM2, APOBEC3A, CIAO1, DDX58, DHX9, IFI16, IFIH1, IFIT1, IFIT3, LRRFIP1, MYD88, OAS1, TLR8, and ZBP1, and / or the second gene expression profile comprising one or more T-Cell receptor signalling genes selected from the group consisting of: CD2, CD247, CD28, CD3E, CD3G, CD4, CSK, EZR, FYN, LAT, LCK, PAG1, PDE4D, PRKACA, PRKACB, PTPRC, and ZAP70, and / or the third gene expression profile comprising one or more PDE4D7 correlated genes selected from the group consisting of: ABCC5, CUX2, KIAA1549, PDE4D, RAP1GAP2, SLC39A11, TDRD1, and VWA2, said gene expression profile being determined in a biological sample obtained from the subject, determining the prediction of the outcome based on the gene expression profile comprising the expression levels of the four or more genes, wherein said prediction is a favourable risk or a non-favourable risk of breast-cancer related death, loco-regional recurrence and / or distant recurrence.

This invention provides a sugarcane with disease resistance function. ScSnRK1.1 Genes, proteins, and applications belong to the field of biotechnology, and specifically disclose sugarcane... ScSnRK1.1 Genes and their application in enhancing disease resistance. This invention relates to... ScSnRK1.1 Preliminary research has been conducted on the response to pathogen stress, and the ability to integrate multiple defense signaling pathways to regulate plant immune defense has provided important theoretical basis and gene resources for molecular breeding of sugarcane to resist disease.

The present invention relates to a malaria vaccine composition designed to elicit an immune response against Plasmodium falciparum by providing proteins or amino acid sequences, including PfGBP130 or PfGBP130-A surface antigen sequences. Upon administration to a human subject, the vaccine composition induces the production of specific anti-malaria antibodies. These antibodies are configured to inhibit the invasion of red blood cells by Plasmodium falciparum parasites and / or the antibodies binding to the antigens can cause the death of the parasites within red blood cells, thereby offering a preventive and / or therapeutic effect against malaria. The composition aims to enhance the immune defense mechanism in humans, reducing the incidence and severity of malaria infections by targeting critical stages of the parasite's lifecycle.

This invention belongs to the field of organic chemistry, specifically providing a class of compounds that can be selectively activated by hypochlorous acid to release hydroxyl groups, along with their preparation methods and applications. These compounds, triggered by HOCl, can efficiently release target molecules containing hydroxyl groups, enabling corresponding treatment, intervention, or functional execution. Simultaneously, these compounds can generate detectable signals such as fluorescence while releasing the charge, allowing for in-situ / real-time monitoring of HOCl levels and the release process in lesion areas, providing a basis for disease assessment and efficacy tracking. These compounds remain relatively inert in normal tissues or when HOCl is at physiological levels, reducing disturbance to HOCl in normal areas and helping to maintain overall HOCl homeostasis and basic immune defense functions. This invention develops a class of compounds that can rapidly respond to hypochlorous acid, release hydroxyl-containing drugs, and monitor disease treatment.